Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
This study is currently recruiting patients.
Sponsored by: | Memorial Sloan-Kettering Cancer Center |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic germ cell tumors that are refractory to cisplatin.
Condition | Treatment or Intervention | Phase |
---|---|---|
adult brain tumor extragonadal germ cell tumor ovarian germ cell tumor Testicular Cancer |
Drug: ixabepilone Procedure: chemotherapy |
Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Ovarian Cancer; Testicular Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Ixabepilone in Patients With Metastatic Cisplatin-Refractory Germ Cell Tumors
OBJECTIVES:
OUTLINE: Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1.3-4 years.
Eligibility
Ages Eligible for Study: 16 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |